Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

ANASTROZOLE

All products: general benefit

Other products in the same Health Canada class (L02B, L02BG) — coverage varies; not interchangeable

  • Exemestane (Aromasin): general benefit
  • Letrozole (Femara): general benefit
  • Abiraterone (Zytiga): general benefit
  • Bicalutamide (Casodex): general benefit, Not a benefit
  • Degarelix (Firmagon): general benefit
  • Flutamide (Euflex): general benefit, Not a benefit

3 more in the class list below

Arimidex · DIN 02224135 · 1mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: innoviCares lists Arimidex (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
Savings card: RxHelp ONE lists ARIMIDEX (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
Limit of one Prescription Drug Card Program / Patient Financial Assistance Card from any adjudicator per DIN and claim submitted. The RxHelpONE card CANNOT be combined with any other card or offer. (Terms of Use) (rxhelp.ca, Sep 10, 2026 ↗)
1 brand, same coverage
Arimidex · DIN 02224135 Manufacturer: AstraZeneca; listing date 1996-12-19 Health Canada: Marketed since 2002-01-25 · brand ARIMIDEX · ATC L02BG03 ANASTROZOLE · form Tablet · route Oral · ingredients ANASTROZOLE 1 MG · company Astrazeneca canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.9522 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43395 · Verify on the e-Formulary ↗ (DIN 02224135)

Source record
DIN 02224135: Arimidex Raw flags: sec3=Y Item: 100000109; group id 144; item number 0243; lccId None; manufacturer id AZC Source form: Tab; strength: 1mg Recorded listing: General benefit Source prices (unrounded): $6.3557; ministry $0.9522 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02224135 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43395
Interchangeable products
Anastrozole · DIN 02351218 · $0.9522 Anastrozole · DIN 02442736 · $0.9522 Anastrozole · DIN 02529904 · $0.9522 Apo-Anastrozole · DIN 02374420 · $0.9522 CCP-Anastrozole · DIN 02458799 · $0.9522 Co Anastrozole · DIN 02394898 · $0.9522 Jamp-Anastrozole · DIN 02339080 · $0.9522 Mar-Anastrozole · DIN 02379562 · $0.9522 Med-Anastrozole · DIN 02379104 · $0.9522 Mint-Anastrozole · DIN 02393573 · $0.9522 Nat-Anastrozole · DIN 02417855 · $0.9522 PMS-Anastrozole · DIN 02320738 · $0.9522 Ran-Anastrozole · DIN 02328690 · $0.9522 Riva-Anastrozole · DIN 02392259 · $0.9522 Sandoz Anastrozole · DIN 02338467 · $0.9522 Taro-Anastrozole · DIN 02365650 · $0.9522
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02224135
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (10:00 ANTINEOPLASTIC AGENTS) and how they are covered

Matched class: 10:00 ANTINEOPLASTIC AGENTS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ABIRATERONE ACETATE, ALTRETAMINE, BUSERELIN ACETATE, BUSULFAN, CAPECITABINE, CHLORAMBUCIL, CYPROTERONE ACETATE, DAUNORUBICIN, DEGARELIX ACETATE, ETOPOSIDE, EXEMESTANE, FLUOROURACIL & SALICYLIC ACID, FULVESTRANT, GOSERELIN ACETATE, HYDROXYUREA, IMATINIB MESYLATE, LETROZOLE, LEUPROLIDE ACETATE, MELPHALAN, MERCAPTOPURINE, MITOTANE, PROCARBAZINE HCL, TEMOZOLOMIDE, THIOGUANINE, TRIPTORELIN PAMOATE Some products covered without a code (check the product listing): BICALUTAMIDE, CYCLOPHOSPHAMIDE, FLUTAMIDE, LOMUSTINE (CCNU), MEGESTROL ACETATE, METHOTREXATE, TAMOXIFEN CITRATE, VINCRISTINE SULFATE 10:00 ANTINEOPLASTIC AGENTS

EXEMESTANE

· 3 products · General benefit · strengths: 25mg · Tab

LETROZOLE

· 20 products · General benefit · strengths: 2.5mg · Tab

ABIRATERONE ACETATE

· 18 products · General benefit · strengths: 250mg, 500mg · Tab

BICALUTAMIDE

· 9 products · Listed, not a benefit (1), General benefit (8) · strengths: 50mg · Tab

DEGARELIX ACETATE

· 2 products · General benefit · strengths: 80mg, 120mg · Pd for Inj-Vial Pk

FLUTAMIDE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 250mg · Tab

FULVESTRANT

· 6 products · General benefit · strengths: 50mg/mL · Inj Sol

TAMOXIFEN CITRATE

· 8 products · General benefit (4), Listed, not a benefit (4) · strengths: 10mg, 20mg · Tab

ENZALUTAMIDE

· 5 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 40mg · Cap

ALTRETAMINE

· 1 products · General benefit · strengths: 50mg · Cap

BUSERELIN ACETATE

· 4 products · General benefit · strengths: 6.3mg, 9.45mg, 1mg/mL · Implant Kit, Inj Sol-5.5mL Pk, Nas Sp-10mL Pk

BUSULFAN

· 1 products · General benefit · strengths: 2mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 10:00 and 34 more
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS ARIMIDEX (anastrozole) is indicated for: • the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer. Approval is based on superior disease-free survival for ARIMIDEX in comparison to tamoxifen. However, overall survival was not significantly different between the two treatments (see 14 CLINICAL TRIALS). • hormonal treatment of advanced breast cancer in postmenopausal women. 1.1 Pediatrics Pediatrics (< 18 years of age): Health Canada has not authorized an indication for pediatric use for ARIMIDEX as safety and efficacy have not been established in this group of patients. 1.2 Geriatrics Geriatrics (> 65 years of age): Evidence from clinical studies and experience suggests that use in the geriatric population is not associated with differences in safety or effectiveness. https://pdf.hres.ca/dpd_pm/00078111.PDF PM date: AUG 1, 1996 Source product: ARIMIDEX; DIN 02224135; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.